On Thursday, Paragon Offshore PLC (NYSE:PGN)’s shares declined -2.79% to $1.74.
Paragon Offshore PLC (PGN) declared that Steven A. Manz, Senior Vice President and Chief Financial Officer of Paragon, will present at the Bank of America Merrill Lynch 2015 Energy and Power Leveraged Finance Conference in New York, New York starting at 8:50 a.m. U.S. Eastern Daylight Time on Wednesday, June 3, 2015. A live webcast and presentation slides will be accessible at the time of the presentation on Paragon’s website at www.paragonoffshore.com, under “Events & Presentations” in the “Investor Relations” section of the website.
Paragon Offshore plc, together with its auxiliaries, provides offshore drilling rigs. The company is involved in contracting its rigs, related equipment, and work crews to conduct oil and gas drilling and workover operations for its exploration and production customers on a day rate basis. Its drilling fleet comprises of 34 jackups and 6 floaters, counting 4 drillships and 2 semisubmersibles.
Basic Energy Services, Inc (NYSE:BAS)’s shares dropped -2.62% to $8.54.
Basic Energy Services, Inc (BAS) declared that its administration will be presenting at the Bank of America Merrill Lynch 2015 Energy and Power Leveraged Finance Conference to be held in New York City on June 2 – 3, 2015.
Basic Energy Services, Inc. provides well site services to oil and natural gas drilling and producing companies in the United States. Its Completion and Remedial Services segment offers pumping services, such as cementing, acidizing, fracturing, nitrogen, and pressure testing; rental and fishing tools; coiled tubing; snubbing services; thru-tubing; cased-hole wireline services; and underbalanced drilling in low pressure and fluid sensitive reservoirs.
At the end of Thursday’s trade, Rowan Companies PLC (NYSE:RDC)‘s shares dipped -2.46% to $21.83.
Rowan Companies PLC (RDC) stated net income of $123.7 million, or $0.99 per share, contrast to $59.6 million, or $0.48 per share in the first quarter of 2014. Net income for the preceding-year quarter comprised of a litigation settlement gain which raised net income from ongoing operations by $20.9 million, or $0.17 per share. The preceding-year quarter also comprised of a gain from suspended operations which raised net income by $4.0 million, or $0.03 per share. Not taking into account the impact of these items, net income for the first quarter of 2014 was $34.7 million or $0.28 per share.
Rowan’s revenues were $547.0 million in the first quarter of 2015, an enhance of 45% over the preceding-year quarter due primarily to the contributions from three of the Company’s newbuild ultra-deepwater drillships. The first two ultra-deepwater drillships began operating in April and October 2014, and the third ultra-deepwater drillship began operating on February 1, 2015.
On May 5, 2015, the Company amended and restated its revolving credit agreement to enhance the borrowing capacity from $1.0 billion to $1.5 billion and to extend the maturity date by one year to January 23, 2020. Commitments during the final year of the agreement decline by $60 million to $1.44 billion.
Tom Burke, President and Chief Executive Officer, stated that they are happy with their first quarter operating results which reflect higher earnings and better margins due to the contributions from three newbuild ultra-deepwater drillships, low out of service time and noteworthy cost control efforts.
Rowan Companies plc provides offshore oil and gas contract drilling services. It operates a fleet of 30 self-elevating mobile offshore jack-up drilling units, in addition to 3 ultra-deepwater drill ships.
Sarepta Therapeutics Inc (NASDAQ:SRPT), ended its Thursday’s trading session with -2.41% loss, and closed at $25.51.
Sarepta Therapeutics Inc (SRPT) declared that the Company held a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding its lead product candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD). Sarepta has agreed with the Agency to initiate a rolling NDA submission and will submit the non-clinical and CMC components of the NDA by the end of this week. As formerly declared, Sarepta plans to submit the final component of the NDA by mid-year 2015.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
